Core Viewpoint - Baicheng Pharmaceutical (301096.SZ) announced that its wholly-owned subsidiary, Zhejiang Saimer Pharmaceutical Co., Ltd., has received clinical trial approval from the National Medical Products Administration (NMPA) for the oral solution BIOS2242, which is aimed at treating cerebral ischemic diseases such as stroke and cerebral infarction [1] Group 1 - The approved drug BIOS2242 oral solution addresses the limitations of traditional solid oral dosage forms like tablets and capsules, which are often unsuitable for patients experiencing swallowing difficulties due to symptoms of cerebral ischemic diseases [1] - The oral solution provides a better medication option for patients, simplifying the administration process and improving the feasibility and accuracy of drug intake [1] - Currently, there are no similar products approved for market release domestically or internationally, indicating a potential competitive advantage for the company [1]
百诚医药：子公司申报的BIOS2242口服溶液获得临床试验批准通知书